These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 19372826

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Technological advances to increase immunogenicity of DNA vaccines.
    Lemieux P.
    Expert Rev Vaccines; 2002 Jun; 1(1):85-93. PubMed ID: 12908515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice.
    Voltan R, Castaldello A, Brocca-Cofano E, De Michele R, Triulzi C, Altavilla G, Tondelli L, Laus M, Sparnacci K, Reali E, Gavioli R, Ensoli B, Caputo A.
    Vaccine; 2009 Jul 16; 27(33):4498-507. PubMed ID: 19450649
    [Abstract] [Full Text] [Related]

  • 6. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP, Sun JF, Li N, Sun Y, Wang Y, Qiu HJ.
    Vet Immunol Immunopathol; 2009 Oct 15; 131(3-4):158-66. PubMed ID: 19411115
    [Abstract] [Full Text] [Related]

  • 7. Recent trends in clinical trials of vaccines to prevent HIV/AIDS.
    Fast PE.
    Curr Opin HIV AIDS; 2006 Jul 15; 1(4):267-71. PubMed ID: 19372820
    [Abstract] [Full Text] [Related]

  • 8. Gene-based vaccines: recent technical and clinical advances.
    Ulmer JB, Wahren B, Liu MA.
    Trends Mol Med; 2006 May 15; 12(5):216-22. PubMed ID: 16621717
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
    Brennan FR, Dougan G.
    Vaccine; 2005 May 02; 23(24):3210-22. PubMed ID: 15837222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A, Mintardjo R, Tax D, Gillissen G, Custers J, Pau MG, Klap J, Santra S, Balachandran H, Letvin NL, Goudsmit J, Radosević K.
    Vaccine; 2009 Oct 19; 27(44):6226-33. PubMed ID: 19686691
    [Abstract] [Full Text] [Related]

  • 19. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus.
    Friedrich TC, Watkins DI.
    Curr Opin HIV AIDS; 2008 May 19; 3(3):393-8. PubMed ID: 19372996
    [Abstract] [Full Text] [Related]

  • 20. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P, Madsen HB, Nielsen HM, Foged C.
    Expert Opin Drug Deliv; 2009 Jul 19; 6(7):657-72. PubMed ID: 19538037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.